SG153039A1 - Crystalline polymorphic forms of monosodium n-[8- (2hydroxybenzoyl)amino]caprylate - Google Patents
Crystalline polymorphic forms of monosodium n-[8- (2hydroxybenzoyl)amino]caprylateInfo
- Publication number
- SG153039A1 SG153039A1 SG200903067-7A SG2009030677A SG153039A1 SG 153039 A1 SG153039 A1 SG 153039A1 SG 2009030677 A SG2009030677 A SG 2009030677A SG 153039 A1 SG153039 A1 SG 153039A1
- Authority
- SG
- Singapore
- Prior art keywords
- caprylate
- monosodium
- amino
- polymorphic forms
- crystalline polymorphic
- Prior art date
Links
- 125000003816 2-hydroxybenzoyl group Chemical group OC1=C(C(=O)*)C=CC=C1 0.000 title 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 title 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 title 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/02—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of powders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/60—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Physiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56947604P | 2004-05-06 | 2004-05-06 | |
| US61941804P | 2004-10-15 | 2004-10-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG153039A1 true SG153039A1 (en) | 2009-06-29 |
Family
ID=35320672
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG200903067-7A SG153039A1 (en) | 2004-05-06 | 2005-05-06 | Crystalline polymorphic forms of monosodium n-[8- (2hydroxybenzoyl)amino]caprylate |
Country Status (15)
| Country | Link |
|---|---|
| US (6) | US8636996B2 (he) |
| EP (3) | EP3058944B1 (he) |
| JP (1) | JP4903690B2 (he) |
| CN (6) | CN102040537A (he) |
| AU (1) | AU2005240213B8 (he) |
| BR (1) | BRPI0510231A (he) |
| CA (2) | CA2897225C (he) |
| EA (1) | EA013518B1 (he) |
| ES (3) | ES2739500T3 (he) |
| HK (5) | HK1153730A1 (he) |
| IL (1) | IL178677A (he) |
| MX (1) | MXPA06012842A (he) |
| NZ (1) | NZ550890A (he) |
| SG (1) | SG153039A1 (he) |
| WO (1) | WO2005107462A2 (he) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8030271B2 (en) | 2005-07-05 | 2011-10-04 | Emisphere Technologies, Inc. | Compositions and methods for buccal delivery of human growth hormone |
| WO2007121318A2 (en) | 2006-04-12 | 2007-10-25 | Emisphere Technologies, Inc. | Formulations for delivering insulin |
| CA2656019C (en) * | 2006-06-28 | 2016-09-13 | Emisphere Technologies, Inc. | Gallium nitrate formulations |
| US9345722B2 (en) * | 2006-07-24 | 2016-05-24 | Emisphere Technologies, Inc. | Pharmaceutical formulations for the treatment of alzheimer's disease |
| CN101506147B (zh) | 2006-09-07 | 2012-03-21 | 霍夫曼-拉罗奇有限公司 | 用于制备snac（n-（8-[2-羟基苯甲酰基]-氨基）辛酸钠）的方法 |
| WO2009059188A1 (en) * | 2007-11-02 | 2009-05-07 | Emisphere Technologies, Inc. | Method of treating vitamin b12 deficiency |
| US20110039930A1 (en) | 2009-08-03 | 2011-02-17 | Emisphere Technologies, Inc. | Fast-acting naproxen composition with reduced gastrointestinal effects |
| EP2538945A4 (en) * | 2010-02-24 | 2013-07-24 | Emisphere Tech Inc | ORAL THERAPY WITH VITAMIN B12 |
| WO2012080471A1 (en) | 2010-12-16 | 2012-06-21 | Novo Nordisk A/S | Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid |
| ES2612278T3 (es) | 2011-04-12 | 2017-05-16 | Novo Nordisk A/S | Derivados de GLP-1 doble-acilados |
| US10933120B2 (en) | 2012-03-22 | 2021-03-02 | Novo Nordisk A/S | Compositions of GLP-1 peptides and preparation thereof |
| ES2715308T3 (es) | 2012-03-22 | 2019-06-03 | Novo Nordisk As | Composiciones que comprenden un agente de suministro y su preparación |
| US9993430B2 (en) | 2012-06-20 | 2018-06-12 | Novo Nordisk A/S | Tablet formulation comprising semaglutide and a delivery agent |
| CN104884065B (zh) | 2012-09-21 | 2019-01-01 | 强烈治疗剂公司 | 治疗癌症的方法 |
| US10954824B2 (en) | 2016-12-19 | 2021-03-23 | General Electric Company | Systems and methods for controlling drum levels using flow |
| EP3746111B1 (en) | 2018-02-02 | 2023-07-19 | Novo Nordisk A/S | Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant |
| CN111517980B (zh) * | 2020-05-14 | 2021-02-09 | 台州浦凯医药科技有限公司 | N-[8-(2-羟基苯甲酰基)氨基]辛酸一钾晶型化合物、制备方法及用途 |
| US20230234916A1 (en) * | 2020-05-29 | 2023-07-27 | Sciwind Biosciences Co., Ltd. | N-[8-(2-hydroxybenzoyl)amino]potassium octanoate crystal polymorph, and preparation method therefor and use thereof |
| JP2022094481A (ja) * | 2020-12-15 | 2022-06-27 | 大阪瓦斯株式会社 | ヒドロキシアルカン酸結晶の製造方法及びヒドロキシアルカン酸の結晶多形体 |
| KR20240035495A (ko) | 2021-07-16 | 2024-03-15 | 노보 노르디스크 에이/에스 | 나트륨 n-(8-(2-하이드록시벤조일)아미노)카프릴레이트 다형체 형태 a |
| CN115108936A (zh) * | 2022-07-29 | 2022-09-27 | 成都普康唯新生物科技有限公司 | 无水体系制备8-(2-羟基苯甲酰胺基)辛酸钠无水晶型的方法 |
| CN117466765B (zh) * | 2023-12-27 | 2024-03-15 | 成都道合尔医药技术有限公司 | 8-(2-羟基苯甲酰胺基)辛酸钠及其合成方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4421685A (en) | 1980-03-27 | 1983-12-20 | Eli Lilly And Company | Process for producing an insulin |
| US5534488A (en) | 1993-08-13 | 1996-07-09 | Eli Lilly And Company | Insulin formulation |
| US5474978A (en) | 1994-06-16 | 1995-12-12 | Eli Lilly And Company | Insulin analog formulations |
| BR9604880A (pt) * | 1995-03-31 | 1998-05-19 | Emisphere Tech Inc | Composto composição forma de unidade de dosagem métodos para administração de um agente biologicamente ativo para preparar uma composição para administração de um agente ativo e para preparar um composto e composição farmacológica |
| US5650386A (en) | 1995-03-31 | 1997-07-22 | Emisphere Technologies, Inc. | Compositions for oral delivery of active agents |
| US5866536A (en) * | 1995-03-31 | 1999-02-02 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| CA2369591C (en) * | 1999-04-05 | 2011-06-14 | Emisphere Technologies, Inc. | Disodium salts, monohydrate, and ethanol solvates |
| US7138546B2 (en) * | 2000-08-18 | 2006-11-21 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| AU2001288277A1 (en) * | 2000-08-18 | 2002-03-04 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| WO2002070438A2 (en) * | 2001-03-01 | 2002-09-12 | Emisphere Technologies, Inc. | Compositions for delivering bisphosphonates |
| JP2002332231A (ja) * | 2001-03-06 | 2002-11-22 | Jiro Takada | γ−ＣＥＨＣ送達剤 |
-
2005
- 2005-05-06 ES ES16161529T patent/ES2739500T3/es active Active
- 2005-05-06 MX MXPA06012842A patent/MXPA06012842A/es active IP Right Grant
- 2005-05-06 CN CN2010105935750A patent/CN102040537A/zh active Pending
- 2005-05-06 BR BRPI0510231-6A patent/BRPI0510231A/pt not_active Application Discontinuation
- 2005-05-06 CN CN201010593589.2A patent/CN102001963B/zh active Active
- 2005-05-06 CA CA2897225A patent/CA2897225C/en not_active Expired - Fee Related
- 2005-05-06 EA EA200602066A patent/EA013518B1/ru unknown
- 2005-05-06 EP EP16161529.9A patent/EP3058944B1/en active Active
- 2005-05-06 WO PCT/US2005/016126 patent/WO2005107462A2/en active Application Filing
- 2005-05-06 CN CN2010105934921A patent/CN102001962B/zh active Active
- 2005-05-06 AU AU2005240213A patent/AU2005240213B8/en not_active Ceased
- 2005-05-06 NZ NZ550890A patent/NZ550890A/en not_active IP Right Cessation
- 2005-05-06 CN CN2010105936039A patent/CN102040538B/zh active Active
- 2005-05-06 CN CN2010105934599A patent/CN102040536B/zh active Active
- 2005-05-06 JP JP2007511696A patent/JP4903690B2/ja active Active
- 2005-05-06 ES ES19180925T patent/ES2879880T3/es active Active
- 2005-05-06 SG SG200903067-7A patent/SG153039A1/en unknown
- 2005-05-06 CN CN2010105934391A patent/CN102040535B/zh active Active
- 2005-05-06 CA CA2563681A patent/CA2563681C/en not_active Expired - Fee Related
- 2005-05-06 EP EP05748026.1A patent/EP1773351B1/en active Active
- 2005-05-06 ES ES05748026T patent/ES2729825T3/es active Active
- 2005-05-06 EP EP19180925.0A patent/EP3572086B1/en active Active
- 2005-05-06 US US11/568,753 patent/US8636996B2/en active Active
-
2006
- 2006-10-17 IL IL178677A patent/IL178677A/he active IP Right Grant
-
2011
- 2011-08-16 HK HK11108634.2A patent/HK1153730A1/xx not_active IP Right Cessation
- 2011-08-16 HK HK11108635.1A patent/HK1153731A1/xx not_active IP Right Cessation
- 2011-11-03 HK HK11111870.9A patent/HK1157318A1/xx not_active IP Right Cessation
- 2011-11-03 HK HK11111869.2A patent/HK1157317A1/xx not_active IP Right Cessation
- 2011-11-03 HK HK11111873.6A patent/HK1157737A1/xx not_active IP Right Cessation
-
2013
- 2013-12-23 US US14/138,787 patent/US9321719B2/en active Active
-
2016
- 2016-02-22 US US15/049,313 patent/US9750710B2/en active Active
-
2017
- 2017-08-03 US US15/668,236 patent/US10188621B2/en active Active
-
2018
- 2018-12-06 US US16/212,428 patent/US10744105B2/en active Active
-
2020
- 2020-07-30 US US16/943,558 patent/US11395809B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL178677A0 (en) | Crystalline polymorphic forms of monosodium n-[8-(2-hdroxybenzoyl)amino] caprylate | |
| HK1093483A1 (en) | Polymorphic form of n- | |
| IL176141A0 (en) | Crystalline forms of valacyclovir hydrochloride | |
| IL172006A0 (en) | Novel crystalline forms of valacyclovir hydrochloride | |
| RS20130524A3 (en) | PROCEDURE FOR OBTAINING AMINO CROTONYL UNITS | |
| IL182727A0 (en) | Amide compound | |
| HK1075044A1 (en) | Crystalline polymorphic form of irinotecan hydrochloride | |
| EP1717225A4 (en) | BICYCLIC AMIDE DERIVATIVES | |
| EP1804582A4 (en) | POLYMORPH SHAPES OF TADALAFIL | |
| IL211935A0 (en) | Salts of isophosphoramide mustard and analogs thereof as anti-tumor agents | |
| IL190483A0 (en) | Methods for use of branched chain amino acids | |
| IL172004A0 (en) | Polymorphic forms of ziprasidone hci and processes for their preparation | |
| IL192360A0 (en) | Crystalline polymorphic forms of olopatadine hydrochloride and processes for their preparation | |
| IL179331A0 (en) | Preparation of levalbuterol hydrochloride | |
| IL176953A0 (en) | Polymorphic forms of nateglinide | |
| HK1148527A1 (en) | Amine salt of carbostyril derivative | |
| AU2003232719A1 (en) | Novel crystalline forms of valacyclovir hydrochloride | |
| IL166592A0 (en) | Novel crystalline forms of gatifloxacin | |
| IL165115A0 (en) | Novel crystalline forms of gatifloxacin | |
| EP1804796A4 (en) | AMINO-SUBSTITUTED ARYLOXYBENZYLPIPERIDINE DERIVATIVES | |
| IL174969A0 (en) | Crystalline forms of (+)-and (-) erythro-mefloquine hydrochloride | |
| EP1632476A4 (en) | ACIDIC ACID SALT OF A CARBAZUCKERAMINE DERIVATIVE | |
| IL166308A0 (en) | Polymorphic forms of nateglinide | |
| PL373802A1 (en) | Polymorphic forms of phenyl oxazolidinone derivatives | |
| IL165690A0 (en) | Novel crystalline forms of gatifloxacin |